93.35
10.79 (13.07%)
| Previous Close | 82.56 |
| Open | 86.76 |
| Volume | 1,809,828 |
| Avg. Volume (3M) | 564,659 |
| Market Cap | 9,896,686,592 |
| Price / Earnings (Forward) | 238.10 |
| Price / Sales | 15.59 |
| Price / Book | 8.79 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -14.07% |
| Operating Margin (TTM) | -22.15% |
| Diluted EPS (TTM) | -0.870 |
| Quarterly Revenue Growth (YOY) | 39.00% |
| Total Debt/Equity (MRQ) | 1.55% |
| Current Ratio (MRQ) | 7.66 |
| Operating Cash Flow (TTM) | -62.16 M |
| Levered Free Cash Flow (TTM) | -6.95 M |
| Return on Assets (TTM) | -7.45% |
| Return on Equity (TTM) | -9.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Intra-Cellular Therapies Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 1.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.40 |
|
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 2.33% |
| % Held by Institutions | 96.14% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (Needham, 7.12%) | Hold |
| Median | 94.50 (1.23%) | |
| Low | 89.00 (JP Morgan, -4.66%) | Buy |
| Average | 94.50 (1.23%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 90.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 13 Jan 2025 | 100.00 (7.12%) | Hold | 94.87 |
| 31 Oct 2024 | 100.00 (7.12%) | Buy | 84.75 | |
| JP Morgan | 04 Nov 2024 | 89.00 (-4.66%) | Buy | 86.17 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |